From respiratory cultures to empirical treatment: Integrating local resistance data, colonization risk, and patient-level factors in hospital-acquired pneumonia
محل انتشار: مجله طب پیشگیری و مکمل، دوره: 5، شماره: 3
سال انتشار: 1405
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 34
فایل این مقاله در 10 صفحه با فرمت PDF قابل دریافت می باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_IJPM-5-3_006
تاریخ نمایه سازی: 21 آبان 1405
چکیده مقاله:
Hospital-acquired pneumonia (HAP) remains a leading cause of nosocomial morbidity and mortality, particularly among mechanically ventilated and critically ill patients, and delays in adequate empirical antimicrobial coverage are independently associated with worsened outcomes. Because culture-based pathogen identification and susceptibility testing require time, clinicians must bridge the resulting uncertainty by integrating local epidemiological data with patient-specific risk assessment.This narrative review examines the interplay among respiratory culture results, local resistance data, colonization dynamics, and patient-level variables in shaping empirical therapy for HAP. Respiratory cultures from endotracheal aspirates or bronchoalveolar lavage remain the microbiological cornerstone of diagnosis and de-escalation, while emerging molecular diagnostics promise to shorten the empirical window. Cumulative antibiograms provide quantitative susceptibility estimates but report organism–drug pairs rather than syndrome-level coverage; weighted-incidence syndromic combination antibiograms (WISCA) address this limitation by incorporating pathogen incidence and combination susceptibility, and have been validated in ventilator-associated pneumonia and other syndromes. Colonization with multidrug-resistant organisms, prior culture results, clinical frailty, and immunocompromised status further modify the probability of resistant pathogens. Inappropriate empirical therapy is consistently associated with excess mortality, whereas guideline-concordant, microbiologically appropriate treatment improves outcomes in multidrug-resistant infections. Robust decision algorithms require deliberate integration of epidemiological, microbiological, and clinical data streams, supported by standardized reporting and bias assessment. Resource-limited and high-resistance settings face amplified challenges, yet cost-effective microbiology services and locally adapted antibiograms remain feasible and essential. Sustained investment in laboratory capacity, clinician education, rapid diagnostics, WISCA adoption, and hospital-wide stewardship interventions offers the most practical pathway to narrowing the gap between respiratory culture results and timely, adequate empirical treatment while minimizing selective pressure for further resistance.
کلیدواژه ها:
Hospital-acquired pneumonia (HAP) ، Empirical antimicrobial therapy ، Weighted-incidence syndromic combination antibiograms (WISCA) ، Multidrug-resistant organisms (MDROs) ، Antimicrobial stewardship
نویسندگان
مراجع و منابع این مقاله:
لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :